Introduction

Species of the genera
1 Due to increased control over the last decade, the number of reported cases has declined to under 10000 in 2009 for the first time in 50 years. 1 For chemotherapy, only four drugs (suramin, pentamidine, melarsoprol and eflornithine), of which three were developed >60 years ago, and one drug combination therapy (eflornithine/nifurtimox) are available. 1, 2 In addition, all drugs have major drawbacks including poor efficacy, significant toxicity, need for parental administration and drug resistance.
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Trypanosoma cruzi is the aetiological agent of Chagas disease in Latin America. More than 25 million people in 19 endemic countries are at risk of contracting Chagas disease and an estimated 10 million people are infected. 6 Only two drugs (nifurtimox and benznidazole)
are available for treatment. 6.7 Both drugs were developed in the 1970s and are only effective in the acute state of the disease (100% effectiveness if given soon after infection). 6 In addition, both medicines have significant side effects, ranging from nausea to life-threatening complications.
The genomes of T. brucei rhodesiense, T. cruzi type VI (CL Brener) and L. major were sequenced in 2005 and two years later those of L. infantum and L. braziliensis [10] [11] [12] [13] , T. b.
gambiense and most recently T. cruzi Type I (Sylvio) have been described in publication. 14, 15 There are several more currently being undertaken and the data from some of these has been pre-released into the databases. Whereas the genomes of T. brucei and Leishmania sp.
contain about 8000-9000 predicted protein-coding genes, that from the hybrid genome of T.
cruzi CL Brenner contained some 1.5 times more, approximately 12000, reflecting large amounts of repetitive DNA such as multicopy genes in tandem array and large multigene families. The Type I T. cruzi contained considerably less of this repetitive DNA making the gene repertoire considerably smaller and more in line with the other kinetoplastids. Overall this group of parasites share some 5000 to 6000 conserved core genes, indicating that the proteins encoded by these genes may provide targets for drugs that could be effective against all these parasites.
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Databases for trypanosomatids
The major. 20 This database was built on the annotated genome sequence of L. major and curated on the basis of literature searches, experimental studies and bioinformatic data. 20 The
LeishCyc database represents a reconstruction of the L. major metabolic network and contains more than 1000 genes that encode for enzymatic or transport reactions. 20 A similar
Drug target discovery using genome information
The availability of the genome sequences of trypanosomatid parasites has set high hopes for the discovery of new drug targets using a reverse pharmacology approach (Fig 1.) .
Reverse pharmacology contrasts with traditional drug discovery by starting with the genome as the source of all potential targets and then eliminating through a series of screens those that are unlikely to provide an effective target for drug design. Central to assessment of a protein as a drug target is that it is "druggable" and that its presence is essential for the organism viability. Once this is established, however, there are two fundamentally different methods by which genome targets are identified and developed from the genome. Some targets are identified as homologous proteins to existing drug targets in other organisms. This approach allows for "piggy-backing" of drug development. Piggy-backing is especially effective for targets of anti-cancer drugs, where a conserved enzyme is essential to parasite survival. Once identified, the task is to highlight variation between the structure of the parasite enzyme and the human enzyme that can serve as the basis for drug specificity and modify inhibitors using medicinal chemistry to tailor them for antiparasitic activity without toxicity to the host. revealed that 30% of the ORFs generated a phenotype, mainly involving cell growth, viability and/or cell cycle progression. 22 RNAi against about 12% of ORFs turned out to be lethal.
As many of the ORFs are associated with growth, their gene products may represent potential drugs targets.
In another study, Alves-Ferreira et al. tried to identify potential new therapeutic targets for Chagas disease through in silico metabolic pathway analysis. 23 They identified analogous and specific enzymes in T. cruzi by comparing the parasite metabolic pathways with the corresponding human metabolic pathways. By focussing on energetic pathways (glycolysis, pentose phosphate shunt, Krebs cycle, oxidative phosphorylation, β-oxidation, amino acid metabolism), lipid pathways and polyamine pathways, they identified several enzymes that are analogous to those of humans. 23 They suggested that many of these enzymes could be potential new drug targets. 23 In a similar study, Capriles and co-workers performed a comparative analysis with the T. cruzi genome and the human genome and used comparative modelling techniques to predict 3D protein structures. 24 They were able to identify 397 T.
cruzi enzyme sequences that are potential candidates for further structure-based drug development. 24 Trypanosomatid parasites lack de novo biosynthesis of purines and depend entirely on the salvage pathway to meet their purine requirements. 25 Because enzymes and transporters of the purine salvage pathway show sufficient differences between trypanosomatids and humans, it is considered as a potential drug target against these parasites. 25 In fact, extensive research on the development of specific inhibitors to target the parasite purine salvage pathway has been carried out over the last two decades. 25 However, based on the genome sequence data, it seems that trypanosomatids possess by-pass mechanisms involving other enzymes and transporters. 26 This poses the question as to whether inhibition of a single enzyme of the purine salvage pathway is enough to kill trypanosomatids or whether inhibition of multiple enzymes by combination therapy would be required.
Using genome sequence data, Camizotti et al. were able to identify and map one locus of L. major associated with resistance to two analogues inhibitors of the ergosterol biosynthesis, itraconazole and ketoconazole. 27 They discovered two potential proteins unrelated to the ergosterol biosynthesis that mediate resistance to itraconazole/ketoconazole in wild-type cells after transfection with a cosmid containing the corresponding gene sequences. 27 This study demonstrated that genome sequences are useful in the identification of genes involved in drug resistance and therefore will be helpful in aiding to develop new strategies for the development of drugs for treatment of trypanosomatid infections.
Discovery of vaccine candidates using genome information
The term "reverse vaccinology" was coined for the application of post-genomic methods to providing improved vaccine candidates. 28, 29 Reverse vaccinology provides a set of alternative and often faster methodologies when compared with more traditional approaches;
where abundant proteins from cultured microbes, often identified as immunogenic using sera from infected or convalescent patients were identified, purified and tested as innocula. Since the publication of the trypanosomatid genomes a number of studies have applied this knowledge to the identification of vaccine candidates for these parasites using reverse vaccinological approaches as outlined in Fig 2. One starting point for reverse vaccinology is to express every protein encoded by a pathogen's genome and test each for protective qualities without any preconceived bias. This approach was first taken for Neisseria meningitidis serogroup B and although laborious showed that the kind of proteins identified in this manner were different to those identified by traditional methods. 34 DNA vaccines provide a mechanism whereby all proteins encoded by a pathogen can be tested without the need for expressing the recombinant protein in bacteria. 35 The whole gene repertoire of a pathogen is cloned into expression plasmid vehicles and inoculated into the model host. The host cells express the parasite protein eliciting immunity and allowing the investigator to evaluate the protection conferred. This approach has been taken for malaria, leishmaniasis, and Chagas Disease yielding some degree of protection in each case and realizing a number of new vaccine candidates. [36] [37] [38] [39] More targeted approaches begin by pre-screening the genomic sequences bioinformatically. Comparative genomics allows highly variable proteins to be eliminated, or conversely epitopes or antigens which are conserved across a species to be identified. 
New Diagnostics
The impact from the initial trypanosomatid genome sequences on diagnosis relates mostly to the discovery of new markers for infection, prognosis and cure (Fig 3) .
Unfortunately, the genomes projects have also elucidated the remarkable genomic plasticity and intraspecific sequence heterogeneity displayed within these ancient protist lineages.
Properties which represent major obstacles for the development of specific and sensitive diagnostic tools and which have highlighted the desirability of re-sequencing from as diverse a range of clinical isolates as possible. Thus, the trypanosomatid genomes have served in formulating and training efficient and effective bioinformatic tools for identifying candidates as molecular markers (Fig. 3) . Because of the small numbers of genomes available for whole genome comparisons, however, bioinformatic methods have been limited in their ability to evaluate the likely robustness of these markers and the degree to which they are likely to be undermined by intraspecies heterogeneity in the sequence of each marker.
Focusing exclusively on pathogenic trypanosomatids, major biological differences are observed between species and/or genotypes within a single species in terms of antigenic diversity, infectivity, pathology, and drug resistance, despite their sharing a variety of genes.
The dilemma of having distinct biology but considerable conservation at the genomic level led to mapping and gene discovery initiatives based largely in genome analysis. 44 The biology of the human infecting trypanosomatids is very different between species. While T.
brucei can be readily detected in the blood with a variety of molecular tests, similar detection of T. cruzi is quite difficult due to reduced blood parasitemia in the acute phase and can be almost impossible in the indeterminate and chronic phase. Furthermore, in Central and South Americas, T. cruzi occurs in sympatry with T. rangeli, which also infects humans and wild mammals causing no pathology, but leading to misdiagnosis. 45 Lack of therapeutic options has meant that historically research priority has been driven to searching for new drug and/or vaccine targets as well as to comprehension of the genetic diversity, including antigenic variation, and to the mechanisms related to pathogenesis or drug resistance. 17 The rationale for discovery of new diagnostic markers usually points to a different direction, looking for unique or species-specific alleles that allow for clear and precise detection and recognition of the etiological agent. Such targets should inform the existence of distinct genotypes within a single host, but may not be implicated on the pathogenesis. The physical characteristics of the marker such as nuclear or kinetoplast localization, copy number, genomic arrangement and intra-and/or interspecific conservancy/variability are the key factors which inform diagnostic utility.
Once the genomes were available, traditional PCR approaches, including nested and multiplex reactions, were tested for a variety of genes. One promising diagnostic methods that has been used for T. brucei diagnosis and characterization, 46 as well as for other pathogens, is the loop-mediated isothermal amplification (LAMP). 47 Based on a conserved sequence in the repetitive insertion mobile element (RIME) of the sub-genus Trypanozoon, the method is based on a multiplex reaction that enhances the amplification of a stem-loop DNA structure reducing the amplification time and increasing specificity. The isothermal reaction (60-65 o C) does not require the use of thermocyclers and the detection of amplification products is visually performed by addition of SYBR Green to the reaction. 46 The system has proven effective for diagnosis even if the detection is based on single copy genes (e.g. PFRA gene 48 ), costs less than other DNA amplification-based methods and has a considerable advantage in being easily performed under field conditions. Nevertheless, transcriptomics and proteomics which are inherently postgenomic are key to the development of future diagnostics and already trypanosomatid transcriptomes and proteomes have been described from single life-cycle stage maps to analysis of complex hostparasite interactions. 49 Comparative transcriptomics and proteomics can be synthesized with this information and used to detect species-specific proteins for diagnostic and prognostic purposes, to identify sub-cellular proteomes, virulence determinants and antigens for molecular and serological diagnosis. 49, 50 Linking genome based observation of allelic variation with serodiagnostic methods to produce strain specific diagnostic and prognostic tests has been recently undertaken, where peptides predicted from genome sequence to contain strain specific epitopes were synthesized and used to evaluate sera from infected patients. 51 The gap between molecular and serological diagnostics is also bridged by bead-based flow-cytometric technology which utilizes a variety of probing molecules, including antibodies, antigens (native or recombinant) and oligonucleotides, that are covalently bound to paramagnetic carboxylated microspheres. 52, 53 Since each probe can be linked to a bead of distinct color, the technology allows simultaneous (multiplex) detection to up to 500 molecules in a single test and consequently diagnosis, typing, subtyping and even assessment of antigenic diversity or drug resistance markers in a single reaction. An initial study compared this technology favorably with ELISA in terms of sensitivity and specificity when recombinant CRA (cytoplasmic repetitive antigen), FRA (flagellar repetitive antigen) and whole T. cruzi cell lysate was used to screen two distinct panels of chagasic patient's sera. 53 
Summary and Outlook
The availability of the trypanosomatid genomes has undoubtedly changed the former gene-by-gene approach to search for drug targets, vaccine candidates and diagnostic markers.
By unveiling interspecific similarity and intraspecific variability, in silico genome analysis has proven to be a revolutionary target-discovery tool. At the present time, discovery and characterization of novel targets for drug design, novel candidates for vaccine development and novel biomarkers for diagnosis are mostly based on gene discovery utilizing bioinformatics based on initial screens which are then followed by laborious, laboratorybased functional analysis and validation. The advent of improved bioinformatic tools, increased numbers of genomes, transcriptomes and proteomes and the deployment of new technologies for high throughput screening, should allow for scaling-up from academic level tests to user-friendly, affordable and precise technologies for even more productive "reverse" drug, vaccine and diagnosis development in the foreseeable future. Non-similarity to host genome
